ADAGAdageneADAG info
$2.33info-15.27%24h
Global rank21135
Market cap$102.13M
Change 7d-
YTD Performance18.88%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Adagene (ADAG) Stock Overview

    Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

    ADAG Stock Information

    Symbol
    ADAG
    Address
    Building C14Suzhou, 215123China
    Founded
    -
    Trading hours
    -
    Website
    https://www.adagene.com
    Country
    πŸ‡¨πŸ‡³ China
    Phone Number
    86 512 8777 3632

    Adagene (ADAG) Price Chart

    -
    Value:-

    Adagene Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.33
    N/A
    Market Cap
    $102.13M
    N/A
    Shares Outstanding
    43.83M
    N/A
    Employees
    248.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org